The potential effect of metformin on fibroblast growth factor 21 in type 2 diabetes mellitus (T2DM)

[1]  Ali I. Al-Gareeb,et al.  Long-term use of metformin and Alzheimer’s disease: beneficial or detrimental effects , 2023, Inflammopharmacology.

[2]  Ali I. Al-Gareeb,et al.  Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: A hidden treasure , 2022, Journal of diabetes.

[3]  Ali I. Al-Gareeb,et al.  The Potential Role of Growth Differentiation Factor 15 in COVID-19: A Corollary Subjective Effect or Not? , 2022, Diagnostics.

[4]  G. Prud’homme,et al.  Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations , 2022, Frontiers in Aging.

[5]  A. Attama,et al.  Enhanced circulation longevity and pharmacodynamics of metformin from surface-modified nanostructured lipid carriers based on solidified reverse micellar solutions , 2022, Heliyon.

[6]  M. Sánchez-Niño,et al.  Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis. , 2022, Kidney international.

[7]  A. Janež,et al.  Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport , 2022, International journal of molecular sciences.

[8]  M. Gillum,et al.  Plasma FGF21 concentrations are regulated by glucose independently of insulin and GLP-1 in lean, healthy humans , 2022, PeerJ.

[9]  A. Mahadevan,et al.  Serum Fibroblast Growth Factor 21 and Growth Differentiation Factor 15: Two sensitive biomarkers in the diagnosis of mitochondrial disorders. , 2021, Mitochondrion (Amsterdam. Print).

[10]  Yunling Wen,et al.  Metformin Alleviates Hepatic Steatosis and Insulin Resistance in a Mouse Model of High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease by Promoting Transcription Factor EB-Dependent Autophagy , 2021, Frontiers in Pharmacology.

[11]  Qianying Liu,et al.  Beta-klotho in type 2 diabetes mellitus: From pathophysiology to therapeutic strategies , 2021, Reviews in Endocrine and Metabolic Disorders.

[12]  M. Roden,et al.  The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments , 2021, Nature Reviews Gastroenterology & Hepatology.

[13]  N. Chattipakorn,et al.  Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels , 2021, Gut and liver.

[14]  V. Sahintürk,et al.  Effects of metformin on lipopolysaccharide induced inflammation by activating fibroblast growth factor 21 , 2021, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[15]  Ali I. Al-Gareeb,et al.  COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin , 2021, Frontiers in Medicine.

[16]  W. S. Denney,et al.  AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients , 2020, Cell reports. Medicine.

[17]  Guoyue Yuan,et al.  Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus , 2020, Journal of cellular physiology.

[18]  H. Morioka,et al.  Development of a long acting FGF21 analogue-albumin fusion protein and its anti-diabetic effects. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[19]  M. Zahoor,et al.  Chemotherapeutic Potential of Carthamus Oxycantha Root Extract as Antidiarrheal and In Vitro Antibacterial Activities , 2020, Antibiotics.

[20]  E. Mikiciuk-Olasik,et al.  An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis. , 2020, European journal of pharmacology.

[21]  T. Quesada-López,et al.  Brown Adipocytes Secrete GDF15 in Response to Thermogenic Activation , 2019, Obesity.

[22]  J. Dushay,et al.  Increased fructose consumption has sex‐specific effects on fibroblast growth factor 21 levels in humans , 2019, Obesity science & practice.

[23]  K. Cusi,et al.  Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. , 2019, The Journal of clinical endocrinology and metabolism.

[24]  Jing Xue,et al.  Basic Research in Diabetic Nephropathy Health Care: A study of the Renoprotective Mechanism of Metformin , 2019, Journal of Medical Systems.

[25]  Qiming Liu,et al.  Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-α/VLCAD pathway , 2019, Lipids in Health and Disease.

[26]  Shaohui Jia,et al.  Metformin‐induced autophagy and irisin improves INS‐1 cell function and survival in high‐glucose environment via AMPK/SIRT1/PGC‐1α signal pathway , 2019, Food science & nutrition.

[27]  T. Jin,et al.  Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output , 2019, EBioMedicine.

[28]  M. Goodson,et al.  Fibroblast Growth Factor-21 Controls Dietary Protein Intake in Male Mice. , 2019, Endocrinology.

[29]  Tianming Liu,et al.  Clinical implication of alterations in serum Klotho levels in patients with type 2 diabetes mellitus and its associated complications. , 2018, Journal of diabetes and its complications.

[30]  L. Cai,et al.  The role of FGF21 in type 1 diabetes and its complications , 2018, International journal of biological sciences.

[31]  Yan Tang,et al.  Fasting exacerbates hepatic growth differentiation factor 15 to promote fatty acid β-oxidation and ketogenesis via activating XBP1 signaling in liver , 2018, Redox biology.

[32]  Chul-woo Yang,et al.  Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation , 2018, Experimental & Molecular Medicine.

[33]  M. Scott,et al.  Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway , 2017, Oncotarget.

[34]  K. Tsintzas,et al.  FGF21 Is an Insulin-Dependent Postprandial Hormone in Adult Humans , 2017, The Journal of clinical endocrinology and metabolism.

[35]  D. Hardie,et al.  The mechanisms of action of metformin , 2017, Diabetologia.

[36]  D. Haro,et al.  Nutritional regulation of fibroblast growth factor 21: from macronutrients to bioactive dietary compounds , 2017, Hormone molecular biology and clinical investigation.

[37]  Dan Yu,et al.  Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes. , 2017, Journal of diabetes and its complications.

[38]  Min Yang,et al.  Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus. , 2017, Journal of diabetes and its complications.

[39]  T. Vilsbøll,et al.  Involvement of glucagon‐like peptide‐1 in the glucose‐lowering effect of metformin , 2016, Diabetes, obesity & metabolism.

[40]  Liying Song,et al.  Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-κB signaling pathway. , 2016, International immunopharmacology.

[41]  P. Leung,et al.  Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus , 2016, Medicinal research reviews.

[42]  Yuan Guo,et al.  Metformin promotes cholesterol efflux in macrophages by up-regulating FGF21 expression: a novel anti-atherosclerotic mechanism , 2016, Lipids in Health and Disease.

[43]  R. DeFronzo,et al.  Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials , 2016, Diabetologia.

[44]  C. Cobelli,et al.  Glucose Variability: Timing, Risk Analysis, and Relationship to Hypoglycemia in Diabetes , 2016, Diabetes Care.

[45]  A. Slusher,et al.  Attenuated fibroblast growth factor 21 response to acute aerobic exercise in obese individuals. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[46]  S. Banerjee,et al.  GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective , 2015, Journal of diabetes research.

[47]  K. Blaslov,et al.  Basal and postprandial change in serum fibroblast growth factor-21 concentration in type 1 diabetic mellitus and in healthy controls , 2015, Endocrine.

[48]  S. Koo,et al.  Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin‐induced insulin‐deficient diabetic mice by restoring brown adipose tissue function , 2015, Diabetes, obesity & metabolism.

[49]  S. Cho,et al.  Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway , 2015, Scientific Reports.

[50]  M. Koulu,et al.  Metformin induces PGC‐1α expression and selectively affects hepatic PGC‐1α functions , 2014, British journal of pharmacology.

[51]  H. Cyphert,et al.  Glucagon Stimulates Hepatic FGF21 Secretion through a PKA- and EPAC-Dependent Posttranscriptional Mechanism , 2014, PloS one.

[52]  K. Grove,et al.  Increased fibroblast growth factor 21 expression in high-fat diet-sensitive non-human primates (Macaca mulatta) , 2014, International Journal of Obesity.

[53]  J. Hald,et al.  Fibroblast Growth Factor 21 (FGF21) and Glucagon-Like Peptide 1 Contribute to Diabetes Resistance in Glucagon Receptor–Deficient Mice , 2013, Diabetes.

[54]  K. Park,et al.  Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation. , 2013, Biochemical and biophysical research communications.

[55]  H. Fu,et al.  The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. , 2013, Cell metabolism.

[56]  A. Xu,et al.  Fibroblast Growth Factor 21 as an emerging metabolic regulator: clinical perspectives , 2013, Clinical endocrinology.

[57]  J. Holst,et al.  Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells , 2013, Journal of Gastroenterology.

[58]  A. Pfeiffer,et al.  Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? , 2013, Diabetologia.

[59]  K. Clément,et al.  Fasting-induced FGF21 is repressed by LXR activation via recruitment of an HDAC3 corepressor complex in mice. , 2012, Molecular endocrinology.

[60]  H. Hansen,et al.  Metformin Stimulates FGF21 Expression in Primary Hepatocytes , 2012, Experimental diabetes research.

[61]  F. Villarroya,et al.  TNF-α represses β-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway. , 2012, Endocrinology.

[62]  H. Yamanaka-Okumura,et al.  Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet. , 2012, The Journal of nutritional biochemistry.

[63]  T. Reinehr,et al.  Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. , 2012, The Journal of clinical endocrinology and metabolism.

[64]  Chunxia Wang,et al.  Effects of activating transcription factor 4 deficiency on carbohydrate and lipid metabolism in mammals , 2012, IUBMB life.

[65]  Gangyi Yang,et al.  The effects of fibroblast growth factor-21 knockdown and over-expression on its signaling pathway and glucose–lipid metabolism in vitro , 2012, Molecular and Cellular Endocrinology.

[66]  A. Xu,et al.  Research Design and Methods , 2005, Hormone Research in Paediatrics.

[67]  D. Drucker,et al.  Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice , 2011, Diabetologia.

[68]  J. Flier,et al.  Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.

[69]  Qing Yang,et al.  Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK–SIRT1–PGC-1α pathway , 2010, Proceedings of the National Academy of Sciences.

[70]  F. Karpe,et al.  Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. , 2009, The Journal of clinical endocrinology and metabolism.

[71]  R. DeFronzo,et al.  Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance , 2009, Diabetes Care.

[72]  A. Pfeiffer,et al.  Free Fatty Acids Link Metabolism and Regulation of the Insulin-Sensitizing Fibroblast Growth Factor-21 , 2009, Diabetes.

[73]  Philippe Froguel,et al.  Functional and genetic analysis in type 2 diabetes of Liver X receptor alleles – a cohort study , 2009, BMC Medical Genetics.

[74]  P. Arner,et al.  FGF21 attenuates lipolysis in human adipocytes – A possible link to improved insulin sensitivity , 2008, FEBS letters.

[75]  Joanne Wang,et al.  Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human Intestine , 2007, Drug Metabolism and Disposition.

[76]  A. Xu,et al.  Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[77]  N. Chinookoswong,et al.  Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. , 2012, Endocrinology.